Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01614782
First received: June 6, 2012
Last updated: October 17, 2014
Last verified: October 2014

June 6, 2012
October 17, 2014
June 2012
October 2012   (final data collection date for primary outcome measure)
  • Number of participants who experienced at least one adverse event [ Time Frame: Up to 49 days ] [ Designated as safety issue: Yes ]
  • Number of participants who discontinued from study drug due to an adverse event [ Time Frame: Up to 21 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01614782 on ClinicalTrials.gov Archive Site
  • Area under the plasma concentration time curve from Hour 0 to Hour 24 (AUC0-24) following once daily administration of MK-5823 [ Time Frame: Predose on Day 1 (baseline) through 672 hours following the initial dose ] [ Designated as safety issue: No ]
  • Maximum plasma concentration (Cmax) following once daily administration of MK-5823 [ Time Frame: Predose on Day 1 (baseline) through 672 hours following the initial dose ] [ Designated as safety issue: No ]
  • Lowest plasma concentration (Ctrough) following once daily administration of MK-5823 [ Time Frame: Predose on Day 1 (baseline) through 672 hours following the initial dose ] [ Designated as safety issue: No ]
  • Time to maximum plasma concentration (Tmax) following once daily administration of MK-5823 [ Time Frame: Predose on Day 1 (baseline) through 672 hours following the initial dose ] [ Designated as safety issue: No ]
  • Apparent terminal half-life (apparent t1/2) following once daily administration of MK-5823 [ Time Frame: Predose on Day 1 (baseline) through 672 hours following the initial dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Healthy Overweight/Obese Subjects and Patients With Type 2 Diabetes Mellitus

The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus (T2DM).

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: MK-5823

    MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.

    In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo.

  • Other: Placebo
    Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
  • Experimental: 0.35 mg MK-5823 - Healthy Participants
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
  • Experimental: 0.7 mg MK-5823 - Healthy Participants
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
  • Experimental: 1.4 mg MK-5823 - Healthy Participants
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
  • Experimental: 2.8 mg MK-5823 - Healthy Participants
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
  • Experimental: 1.4 mg MK-5823 - Participants with T2DM
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
  • Experimental: 2.8 mg MK-5823 - Participants with T2DM
    Interventions:
    • Drug: MK-5823
    • Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
24
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female of non-childbearing potential
  • A Body Mass Index between 27 and 35 kg/m^2 and weighs at least 50 kg
  • Judged to be in good health and for the T2DM Panels, good health other than the diagnosis of T2DM
  • For T2DM Panels only: has a diagnosis of T2DM and is being treated with lifestyle management (e.g. diet and exercise) alone or in combination with a stable dose of metformin
  • A nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion Criteria:

  • History of stroke, chronic seizures or major neurological disorder
  • History of clinically significant gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
  • History of clinically significant endocrine abnormalities or diseases (including type I or type II, or steroid-induced diabetes for healthy participant panel; and excluding T2DM for the T2DM Panels)
  • Irritable bowel syndrome, or recurrent nausea, vomiting, diarrhea, or abdominal pain.
  • History of neoplastic disease
  • History of cataracts, diabetic retinopathy, macular edema, macular degeneration, vitreous hemorrhage, glaucoma, ocular surgery, ocular trauma or blindness
  • Requires treatment with systemic or ocular corticosteroids
  • For T2DM Panels, a history of hypoglycemic unawareness
  • For T2DM Panels, active treatment with any anti-hyperglycemic drug other than metformin
  • For T2DM Panels, treatment with any peroxisome proliferator-activated receptor-gamma agonist (e.g. Avandia or Actos) within 12 weeks of study participation
  • Unable to refrain from using any medication beginning 2 weeks before study participation
  • Consumes excessive amounts of alcohol (>3 per day)
  • Consumes more than 6 caffeinated beverages per day
  • Had major surgery or donated or lost more than 1 unit of blood
  • Participated in another investigational study within 4 weeks of study participation
  • History of significant multiple and/or severe allergies or anaphylactic reaction
  • Hypersensitivity to glucagon or insulin
  • Uses illicit drugs or has a history of drug or alcohol abuse within 3 months of study participation
  • Woman of child-bearing potential or is a nursing mother
  • For T2DM Panels, age >50 years
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01614782
5823-002
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP